Articles from Ray Therapeutics

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will support the company’s ongoing clinical development of RTx-015 for the treatment of retinitis pigmentosa (RP), a progressive and debilitating inherited retinal disease that leads to blindness.

Ray Therapeutics, a leading optogenetics company, announced today the appointment of Christopher Whitmore as Chief Financial Officer.

Ray Therapeutics, a leading optogenetics company, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support development of RTx-021, an optogenetic therapy for the treatment of geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).

Ray Therapeutics, a leading optogenetics medicines company, today announced the promotion of Jenny Holt to Chief Development Officer.

Ray Therapeutics, a leading optogenetics company, today announced an upsized and oversubscribed $100M Series A financing round led by Novo Holdings A/S, and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and existing investor 4BIO Capital. The funding will advance multiple programs targeting blinding diseases of the eye through clinical development.

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, announced today that Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer, will present at two upcoming scientific conferences: the 2023 Cell & Gene Meeting on the Med and the Eighth Annual Retinal Cell and Gene Therapy Innovation Summit (held during the 2023 ARVO Annual Meeting).

Ray Therapeutics, a biotech company whose mission is to restore vision to patients with blinding eye diseases, today announced the appointment of Peter Francis, M.D., Ph.D., as Chief Scientific & Medical Officer, and Jenny Holt as Senior Vice President, Program Portfolio Management.

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support development of Ray-001, an optogenetic therapy for the treatment of retinitis pigmentosa and other inherited retinal diseases.

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.